Adverum Biotechnologies, Inc. (ADVM) Just Recorded A Sigfniciant Increase

March 14, 2018 - By Hazel Jackson

The stock of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is a huge mover today! The stock increased 5.76% or $0.4 during the last trading session, reaching $7.35. About 1.34M shares traded. Adverum Biotechnologies, Inc. (NASDAQ:ADVM) has declined 30.48% since March 14, 2017 and is downtrending. It has underperformed by 47.18% the S&P500.
The move comes after 6 months positive chart setup for the $456.97 million company. It was reported on Mar, 14 by We have $8.01 PT which if reached, will make NASDAQ:ADVM worth $41.13 million more.

Analysts await Adverum Biotechnologies, Inc. (NASDAQ:ADVM) to report earnings on May, 8. They expect $-0.29 earnings per share, up 23.68 % or $0.09 from last year’s $-0.38 per share. After $-0.32 actual earnings per share reported by Adverum Biotechnologies, Inc. for the previous quarter, Wall Street now forecasts -9.38 % EPS growth.

More notable recent Adverum Biotechnologies, Inc. (NASDAQ:ADVM) news were published by: which released: “3 Growth Stocks for In-the-Know Investors” on March 14, 2018, also with their article: “Adverum Biotechnologies Announces Closing of $69 Million Public Offering” published on February 12, 2018, published: “Premarket analyst action – healthcare” on February 15, 2018. More interesting news about Adverum Biotechnologies, Inc. (NASDAQ:ADVM) were released by: and their article: “Adverum Biotechnologies Reports Fourth Quarter 2017 Financial Results and …” published on March 06, 2018 as well as‘s news article titled: “Adverum Biotechnologies Announces Completion of Dosing of First Cohort of …” with publication date: February 26, 2018.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has market cap of $456.97 million. The firm has a pipeline that includes product candidates to treat wet age-related macular degeneration , alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. It currently has negative earnings. The Company’s lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: